Biotechnology News and Research

RSS

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Amarantus BioSciences, Inc., a biotechnology company developing new disease-modifying treatments and diagnostics for Parkinson's disease and Traumatic Brain Injury centered on its proprietary anti-apoptosis therapeutic protein MANF, today announced that the Company has successfully completed experiments demonstrating that MANF has an excellent diffusion profile in the striatum of rat brains.

27 Nov 2012

Kinexus releases new antibody microarray kit

Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced today the release of its first Kinex antibody microarray kit with its latest generation KAM-850 chip.

27 Nov 2012

National Taiwan University Hospital, PAREXEL establish alliance

PAREXEL International Corporation a leading global biopharmaceutical services provider, and the National Taiwan University Hospital (NTUH) announced today that they have established an alliance. Under the agreement, PAREXEL and NTUH will collaborate to provide drug development services in Taiwan.

From Parexel 27 Nov 2012

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470 for the treatment of ulcerative colitis.

27 Nov 2012

Rhythm raises additional $8 million to complete Series B financing

Rhythm announced today that the company has raised an additional $8 million to complete a $33 million Series B financing.

27 Nov 2012

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Liver disease is a very broad family of diseases. There are two main categories of liver disease:

27 Nov 2012

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

Thomas Jefferson University will honor the renowned biotech researcher whose discoveries led to a slew of innovative drugs that revolutionized treatment including Herceptin-one of the first gene-based medications for breast cancer-with its prestigious Lennox K. Black International Prize for Excellence in Biomedical Research.

27 Nov 2012

California researchers develop new strategy to find novel antibiotics for bacterial infections

Researchers at the University of California, Santa Cruz, have developed a new strategy for finding novel antibiotic compounds, using a diagnostic panel of bacterial strains for screening chemical extracts from natural sources.

27 Nov 2012

Patheon announces cash tender offer for all outstanding 8.625% Senior Secured Notes

Patheon Inc., a leading provider of contract development and manufacturing services to the global pharmaceutical industry, announced today that it is commencing a cash tender offer for any and all of its outstanding 8.625% Senior Secured Notes due 2017 (CUSIP Numbers 70319W AA6 (Rule 144A) and C7197E AA2 (Regulation S)), upon the terms and subject to the conditions set forth in the Offer to Purchase, dated the date hereof, and in the related Letter of Transmittal.

27 Nov 2012

Experimental flu vaccine technique could reduce time needed to develop new shots for humans

"An experimental vaccine based on a molecule related to DNA protects animals against influenza and may one day offer an ultra-rapid way to develop new shots for humans, German scientists reported on Sunday," Reuters reports.

27 Nov 2012

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Seattle Genetics, Inc. announced today that ADCETRIS (brentuximab vedotin) has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of mycosis fungoides (MF). MF is the most common type of cutaneous T-cell lymphoma (CTCL).

26 Nov 2012

Alnylam advances Tuschl II patent estate through the USPTO

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that the United States Patent and Trademark Office has issued Notices of Allowance for three patent applications from the company's exclusively held Tuschl II patent estate.

26 Nov 2012

mRNA vaccines offer protection against influenza A virus infections in various animal models

CureVac GmbH, a clinical stage biopharmaceutical company developing a new class of therapies and vaccines based on mRNA, and the German Federal Research Institute for Animal Health, Friedrich-Loeffler-Institute (FLI), Germany, today announced that mRNA vaccines (RNActive) based on the company's RNA technology platform have the potential to provide effective protection against infectious diseases.

26 Nov 2012

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Lymphopenia is when you lack the T cells of your immune system. T cells are very important for controlling infection. Probably the most known cause of lymphopenia is HIV.

23 Nov 2012

Allon Files Preliminary Shelf Prospectus

Allon Therapeutics Inc. has filed a preliminary short form base shelf prospectus with the securities commissions in each province and territory of Canada (other than Quebec).

23 Nov 2012

Collaborative research on fruits that may help improve vascular health

Scientists at the University of Warwick and consumer goods manufacturer Unilever are joining forces to identify whether the nutrients in everyday fruit and vegetables could help to improve people's cardiovascular health and protect them from Type-2 diabetes.

23 Nov 2012

UPC teams conduct research in biomedical engineering to improve people's health

Systems to improve patient rehabilitation, methods that help detect diseases, and smart biomaterials for optimising treatments—scientific advances in the field of biomedical engineering are unstoppable. A number of leading UPC teams are carrying out research aimed at harnessing technology to improve people's health.

23 Nov 2012

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

The Belgian biotechnology company, Cardio3 BioSciences (C3BS), a leader in the discovery and development of regenerative and protective therapies for the treatment of cardiac diseases, today announces it has received authorization from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to begin its Congestive Heart failure Cardiopoietic Regenerative Therapy (CHART-1) European Phase III trial for C3BS-CQR-1 in Belgium.

22 Nov 2012

Breakthrough in heart research

Breakthrough in heart research: The research team from Professor Katja Schenke-Layland of the Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB in Stuttgart has discovered cell surface markers that enable the identification and isolation of living functional cardiovascular progenitor cells (CPCs).

22 Nov 2012

DiscoGnosis project aims to develop rapid malaria test

An estimated 500 million people become infected with malaria each year. The disease is often lethal - particularly in tropical developing countries with insufficient health care services. The infected suffer from a high fever. As this is also the case with other germs, however, it is important to conduct a rapid and precise analysis to determine the cause of the disease for a successful therapy.

22 Nov 2012

Biotechnology News and Research

Amarantus demonstrates excellent diffusion profile of MANF in the striatum of rat brains

Kinexus releases new antibody microarray kit

National Taiwan University Hospital, PAREXEL establish alliance

FDA clears Avaxia’s AVX-470 IND for treatment of ulcerative colitis

Rhythm raises additional $8 million to complete Series B financing

Liver disease therapies: an interview with Eric Halioua, CEO of Promethera Biosciences

Renowned biotech researcher to receive TJU's Lennox K. Black International Prize

California researchers develop new strategy to find novel antibiotics for bacterial infections

Patheon announces cash tender offer for all outstanding 8.625% Senior Secured Notes

Experimental flu vaccine technique could reduce time needed to develop new shots for humans

FDA grants Seattle Genetics orphan drug designation for ADCETRIS to treat mycosis fungoides

Alnylam advances Tuschl II patent estate through the USPTO

mRNA vaccines offer protection against influenza A virus infections in various animal models

Lymphopenia driven diseases and the orphan drug industry: an interview with Damian Marron, CEO of Cytheris

Allon Files Preliminary Shelf Prospectus

Collaborative research on fruits that may help improve vascular health

UPC teams conduct research in biomedical engineering to improve people's health

Belgian FAMHP authorizes C3BS Phase III Congestive Heart failure Cardiopoietic Regenerative Therapy trial

Breakthrough in heart research

DiscoGnosis project aims to develop rapid malaria test

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News